Literature DB >> 31264950

Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial.

Eva Schönenberger1, Peter Martus1, Maria Bosserdt1, Elke Zimmermann1, Rudolf Tauber1, Michael Laule1, Marc Dewey1.   

Abstract

Background In the absence of randomized studies, it has been controversial whether the likelihood of acute kidney injury (AKI) differs between intravenous and intra-arterial contrast agent administration. Purpose To compare intravenous versus intra-arterial contrast agent administration in relationship to AKI and analyze the association between AKI and chronic kidney disease (defined as at least mildly decreased estimated glomerular filtration rates [eGFRs]). Materials and Methods This was a prospective study (ClinicalTrials.gov: NCT00844220) that involved randomizing participants with atypical chest pain and suspected coronary artery disease (CAD) between February 2009 and August 2015 to undergo coronary CT angiography with intravenous contrast agent administration or cardiac catheterization angiography with intra-arterial contrast agent administration. This prespecified secondary analysis compared AKI (serum creatinine increase of ≥ 25% or 0.5 mg/dL after 18-24 or 46-50 hours) determined by blinded investigators using absolute differences and relative risks, including two-sided 95% confidence intervals (CIs). Results A total of 320 participants (163 [50.9%] women; mean age, 60 years ± 11) were included. Baseline eGFR did not differ between the CT angiography group (84.3 mL/min/1.73 m2 ± 17.2) and the catheterization group (87.1 mL/min/1.73 m2 ± 16.7) (P = .14). AKI occurred in nine of 161 participants in the CT angiography group (5.6%; 95% CI: 3%, 10%) and in 21 of 159 participants in the catheterization group (13.2%; 95% CI: 9%,19%) (relative risk, 2.4; 95% CI: 1.1, 5.0; P = .02). Also in the subgroup of participants without obstructive CAD, in those not requiring coronary interventions, AKI was more common in the catheterization group (11.9%; 95% CI: 8%, 19%) than in the CT angiography group (4.3% [95% CI: 2%, 9%]; difference, 7.7% [95% CI: 1.3%, 14.1%]; relative risk, 2.8 [95% CI: 1.1, 7.0]; P = .02). Obstructive CAD (odds ratio [OR]: 2.7 [95% CI: 1.1, 6.6]; P = .02), femoral catheter access (OR: 2.5 [95% CI: 1.1, 5.6]; P = .04), and cine ventriculography were associated with AKI (OR: 2.3 [95% CI: 1.0, 4.9]; P = .03). In multivariable analysis, the presence of postcontrast AKI was associated with chronic kidney disease (hazard ratio: 12.4 [95% CI: 4.5, 34.6]; P < .01). Conclusion Acute kidney injury was more common after cardiac catheterization than after CT angiography in this prospective randomized study of patients suspected of having coronary artery disease. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Einstein and Newhouse in this issue.

Entities:  

Year:  2019        PMID: 31264950     DOI: 10.1148/radiol.2019182220

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

Review 1.  [Contrast medium-induced acute kidney injury-Consensus paper of the working group "Heart and Kidney" of the German Cardiac Society and the German Society of Nephrology].

Authors:  J Latus; V Schwenger; G Schlieper; H Reinecke; J Hoyer; P B Persson; B A Remppis; F Mahfoud
Journal:  Internist (Berl)       Date:  2020-12-21       Impact factor: 0.743

2.  Canadian Association of Radiologists Guidance on Contrast-Associated Acute Kidney Injury.

Authors:  D Blair Macdonald; Casey D Hurrell; Andreu F Costa; Matthew D F McInnes; Martin O'Malley; Brendan J Barrett; Pierre Antoine Brown; Edward G Clark; Anastasia Hadjivassiliou; Iain Donald Craik Kirkpatrick; Jeremy Rempel; Paul Jeon; Swapnil Hiremath
Journal:  Can J Kidney Health Dis       Date:  2022-05-24

3.  [Diffusion-weighted magnetic resonance imaging instead of contrast-enhanced imaging for evaluating immediate therapeutic efficacy of high-intensity focused ultrasound ablation of adenomyosis].

Authors:  Y Cui; L Yao; M Feng; J Zhang; D Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-10-20

4.  The Incidence of Contrast-Induced Nephropathy and the Need of Dialysis in Patients Receiving Angiography: A Systematic Review and Meta-Analysis.

Authors:  Mei-Yi Wu; Wei-Cheng Lo; Yun-Chun Wu; Tsu-Chen Lin; Chun-Hung Lin; Mai-Szu Wu; Yu-Kang Tu
Journal:  Front Med (Lausanne)       Date:  2022-04-27

5.  Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty: A systematic review and meta-analysis (PRISMA).

Authors:  Ashkan Heshmatzadeh Behzadi; Behzad Amoozgar; Shalini Jain; Noel Velasco; Umar Zahid; Hamidreza Abbasi; Lutfi Alasadi; Martin R Prince
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

6.  Acute Kidney Injury Following Transcatheter Aortic Valve Implantation: Association with Contrast Media Dosage and Contrast Media Based Risk Predication Models.

Authors:  Doron Sudarsky; Yarden Drutin; Fabio Kusniec; Liza Grosman-Rimon; Ala Lubovich; Wadia Kinany; Evgeni Hazanov; Michael Gelbstein; Edo Y Birati; Ibrahim Marai
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

7.  A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol: part 2-intra-arterial administration.

Authors:  Aart J van der Molen; Ilona A Dekkers; Ibrahim Bedioune; Elisabeth Darmon-Kern
Journal:  Eur Radiol       Date:  2022-03-21       Impact factor: 7.034

Review 8.  Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.

Authors:  Pranab M Barman; Lisa B VanWagner
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.298

9.  Increased fibrotic signaling in a murine model for intra-arterial contrast-induced acute kidney injury.

Authors:  Amit Sharma; Sreenivasulu Kilari; Chuanqi Cai; Michael L Simeon; Sanjay Misra
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.